Transgene Biotek reports ₹21 lakh revenue as legal battles drag on
The nano-cap firm posted a net loss of ₹165.29 lakhs for FY26, with auditors flagging a material risk to its status as a going concern.
— 1 earlier story on Transgene Biotek Ltd. →What's new
- Transgene Biotek generated only ₹21.12 lakhs in revenue for FY26.
- The company recorded a net loss of ₹165.29 lakhs.
- Appeals regarding SEBI recovery proceedings are adjourned until July 2026.
Why this matters
The company is effectively at a standstill. With a market valuation of ₹24 crores and mounting losses, the auditor's warning about the company's ability to continue as a going concern is the most important detail in these results.
What we're watching
- The outcome of SAT and ED tribunal hearings in July 2026.
- Any signs of liquidity to fund operations beyond the current fiscal year.
- Further auditor commentary on the company's long-term viability.
The full read
Transgene Biotek is in a state of operational paralysis. The company's audited results for the fiscal year ended March 31, 2026, show revenue of just ₹21.12 lakhs and a net loss of ₹165.29 lakhs. For a business with a market valuation of ₹24 crores, these figures confirm a near-standstill. The auditor issued an unmodified opinion, yet the notes to the account carry a clear warning regarding the company's status as a going concern. Legal hurdles remain the primary focus. Appeals filed with the Securities Appellate Tribunal and the Appellate Tribunal regarding SEBI recovery proceedings are now adjourned until July 2026. These results offer no path to recovery and confirm the company's ongoing distress. The open question is whether the business can survive its current legal and financial constraints.
Questions answered
- What were the key financial results for Transgene Biotek in FY26?
- The company reported annual revenue of ₹21.12 lakhs and a net loss of ₹165.29 lakhs for the year ended March 31, 2026.
- What is the status of the company's legal challenges?
- Appeals filed with the Securities Appellate Tribunal and the Appellate Tribunal regarding SEBI recovery proceedings remain active and have been adjourned to July 2026.
- Did the auditor raise concerns about the company's future?
- Yes, while the auditor provided an unmodified opinion, the financial statements explicitly highlight a significant risk to the company's ability to continue as a going concern.
- How does the company's revenue compare to its market valuation?
- The company generated only ₹21.12 lakhs in revenue against a market valuation of ₹24 crores.
Story so far
All notes on TRABI →- 29 May 2026 · 3:19 PM IST Transgene Biotek reports ₹21 lakh revenue as legal battles drag on
- 1d ago Transgene Biotek reports widening losses and negative equity in FY26